Physician profile

John Chidester

Malvern, PA

NPI 1124013586

$312.55

in general payments reported to CMS, 2019-2025

5 companies · $20.41 in 2025

The $20.41 reported for 2025 was less than what a typical provider received nationally.

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$146.38

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Stryker Corporation $118.91 2019
Ferring Pharmaceuticals INC. $101.01 2022-2023 Euflexxa
Zimmer Biomet Holdings, INC. $43.01 2023 Gel-One Cross-Linked Hyaluronate
Heron Therapeutics, INC. $29.21 2022
Depuy Synthes Sales INC. $20.41 2025 Orthovisc

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

John Chidester

$312.55

in general payments reported 2019-2025

Years
2019-2025
Top company
Stryker Corporation
Context
The $20.41 reported for 2025 was less than what a typical provider received nationally.

https://glasscript.com/doctor/1295445/john-chidester

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.